Perospirone augmentation of paroxetine in treatment of refractory obsessive–compulsive disorder with depression

Otsuka, Tatsui; Togo, Takashi; Sugiyama, Naoya; Uehara, Kumi; Yoshimi, Asuka; Karashima, Aya; Shioya, Hiromi; Hirayasu, Yoshio

doi:10.1016/j.pnpbp.2006.10.014

Cited by 8 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In long-term and relapse prevention studies, escitalopram, fluoxetine, paroxetine, sertraline and clomipramine were superior to placebo (see above for references). Within the limits of the acute treatment phase, response to treatment with SSRIs is characteristi- SSRI Pallanti et al 1999 Yes (C1) Addition of an SSRI to clomipramine Ravizza et al 1996 Yes (C1) Adding lithium to clomipramine * Rasmussen 1984 Yes (C1) Addition of buspirone to an* SSRI Jenike et al 1991b;Markovitz et al 1990 Yes (C1) Addition of topiramate to an SSRI Hollander and Dell'Osso, 2006;Van Ameringen et al 2006 Yes (C1) Addition of N-acetylcysteine to an SSRI Lafleur et al 2006 Yes (C2) Addition of atypical antipsychotics Á aripiprazole Á olanzapine, Á perospirone, Á quetiapine, or Á risperidone, to an SSRI or clomipramine Agid and Lerer 1999; Atmaca et al 2002;Bogan et al 2005;Bogetto et al 2000;da Rocha and Correa 2007;Dell'Osso et al 2006;Francobandiera, 2001;Friedman et al 2007b;Kawahara et al 2000;Koran et al 2000;Marazziti and Pallanti 1999;Marazziti et al 2005;Mohr et al 2002;Otsuka et al 2007;Pfanner et al 2000;Ravizza et al 1996;Saxena et al 1996;Stein et al 1997;Storch et al 2008;Weiss et al 1999;Yoshimura et al 2006 Yes (C1) cally partial. Between 30 and 60% cases in acute phase DBPC studies reached a clinically relevant level of improvement.…”

Section: Other Medicationsmentioning

confidence: 99%

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

Bandelow

Zohar

Hollander

et al. 2008

The World Journal of Biological Psychiatry

711

410

View full text Add to dashboard Cite

In this report, which is an update of a guideline published in 2002 (Bandelow et al. 2002, recommendations for the pharmacological treatment of anxiety disorder, obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD) are presented. Since the publication of the first version of this guideline, a substantial number of new randomized controlled studies of anxiolytics have been published. In particular, more relapse prevention studies are now available that show sustained efficacy of anxiolytic drugs. The recommendations, developed by the World Federation of Societies of Biological Psychiatry (WFSBP) Task Force for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders, a consensus panel of 30 international experts, are now based on 510 published randomized, placebo-or comparator-controlled clinical studies (RCTs) and 130 open studies and case reports. First-line treatments for these disorders are selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs) and the calcium channel modulator pregabalin. Tricyclic antidepressants (TCAs) are equally effective for some disorders, but many are less well tolerated than the SSRIs/ SNRIs. In treatment-resistant cases, benzodiazepines may be used when the patient does not have a history of substance abuse disorders. Potential treatment options for patients unresponsive to standard treatments are described in this overview. Although these guidelines focus on medications, non-pharmacological were also considered. Cognitive behavioural therapy (CBT) and other variants of behaviour therapy have been sufficiently investigated in controlled studies in patients with anxiety disorders, OCD, and PTSD to support them being recommended either alone or in combination with the above medicines.

show abstract

Section: Other Medicationsmentioning

confidence: 99%

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

Bandelow

Zohar

Hollander

et al. 2008

The World Journal of Biological Psychiatry

711

410

View full text Add to dashboard Cite

show abstract

“…Additionally, considering the many cognitive distortions that are often present with depression (Beck, Rush, Shaw, & Emery, 1987) and OCD (Wilhelm & Steketee, 2006), it might also be effective to explore and/or challenge cognitive distortions that may be interfering with exposure therapy in the hope that these clients will be better able to engage in therapy once their cognitive distortions have been modified. For clients with moderate to severe depression, sequential medication management may be beneficial (Otsuka et al, 2007). In the case of Chuck, a patient with severe contamination fears associated with coming into contact with chemicals, he became depressed during an exposure in which he was asked to spray a common household cleaner.…”

Section: Failure To Habituatementioning

confidence: 99%

When Exposures Go Wrong: Trouble-Shooting Guidelines for Managing Difficult Scenarios that Arise in Exposure-Based Treatment for Obsessive-Compulsive Disorder

Pence¹,

Sulkowski

Jordan

et al. 2010

APT

View full text Add to dashboard Cite

Cognitive-behavioral therapy (CBT) with exposure and ritual prevention (ERP) is widely accepted as the most effective psychological treatment for obsessive compulsive disorder (OCD). However, the extant literature and treatment manuals cannot fully address all the variations in client presentation, the diversity of ERP tasks, and how to negotiate the inevitable therapeutic challenges that may occur. Within this article, we attempt to address common difficulties encountered by therapists employing exposure-based therapy in areas related to: 1) when clients fail to habituate to their anxiety, 2) when clients misjudge how much anxiety an exposure will actually cause, 3) when incidental exposures happen in session, 4) when mental or covert rituals interfere with treatment, and 5) when clients demonstrate exceptionally high sensitivities to anxiety. The goal of this paper is to bridge the gap between treatment theory and practical implementation issues encountered by therapists providing CBT for OCD.

show abstract

Perospirone augmentation of escitalopram in the treatment of an adolescent sophophobia (fear of learning) patient

Miyazaki

2022

Neuropsychopharm Rep

View full text Add to dashboard Cite

Fear and anxiety are normal emotions in children during growth and development. In some cases, however, fear causes significant distress and functional impairment. Here, we present a case of sophophobia (fear of learning) in an adolescent patient, in whom augmentation of escitalopram with perospirone was useful. This is the first case report of sophophobia. Both the patient and his guardian provided permission to publish the features of his case, and the identity of the patient has been protected. | HIS TORY OF PRE S ENT ILLNE SSThe patient was a 15-year-old boy. His family history was unremarkable. His prenatal, postnatal, and early developmental history was unremarkable. He had no history of mental illness or any previous psychiatric treatment. He had no history of smoking, drinking alcohol, or consuming any stimulants.At the age of 14, studying elicited anxiety and panic-like symptoms, including shortness of breath, tightness in his chest, and palpitations. As a result, he began to avoid situations that required studying. He had visited another pediatric clinic where lorazepam was started at the dose of 0.5 mg/day, as needed. However, he showed only transient and partial improvement with lorazepam.Lorazepam was discontinued. Hence, he consulted our clinic at the age of 15.

show abstract

Perospirone augmentation of paroxetine in treatment of refractory obsessive–compulsive disorder with depression

Cited by 8 publications

References 20 publications

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

When Exposures Go Wrong: Trouble-Shooting Guidelines for Managing Difficult Scenarios that Arise in Exposure-Based Treatment for Obsessive-Compulsive Disorder

Perospirone augmentation of escitalopram in the treatment of an adolescent sophophobia (fear of learning) patient

Contact Info

Product

Resources

About